The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission authorised the use of an esketamine nasal spready beneath the manufacturer name Spravato to treat melancholy. Having said that, as of 2021, ketamine has not been accredited via the FDA to treat depression or other mental wellbeing disorders, and therefore, the medica… Read More